Literature DB >> 23002339

Emerging roles of the ribonucleotide reductase M2 in colorectal cancer and ultraviolet-induced DNA damage repair.

Ai-Guo Lu1, Hao Feng, Pu-Xiong-Zhi Wang, Ding-Pei Han, Xue-Hua Chen, Min-Hua Zheng.   

Abstract

AIM: To investigate the roles of the ribonucleotide reductase M2 (RRM2) subunit in colorectal cancer (CRC) and ultraviolet (UV)-induced DNA damage repair.
METHODS: Immunohistochemical staining of tissue microarray was performed to detect the expression of RRM2. Seven CRC cell lines were cultured and three human colon cancer cell lines, i.e., HCT116, SW480 and SW620, were used. Reverse transcription polymerase chain reaction and Western blotting were performed to determine the mRNA and protein expression levels of RRM2, respectively. Cell proliferation assay, cell cycle analysis were performed. Cell apoptosis was evaluated by double staining with fluorescein isothiocyanate-conjugated Annexin V and propidium iodide (PI) using Annexin V/PI apoptosis kit. The motility and invasion of CRC cells were assessed by the Transwell chamber assay. Cells were irradiated with a 254 nm UV-C lamp to detect the UV sensitivity after RRM2 depletion.
RESULTS: Immunohistochemical staining revealed elevated RRM2 levels in CRC tissues. RRM2 overexpression was positively correlated with invasion depth (P < 0.05), poorly differentiated type (P = 0.0051), and tumor node metastasis stage (P = 0.0015). The expression of RRM2 in HCT116 cells was downregulated after transfection, and HCT116 cell proliferation was obviously suppressed compared to control groups (P < 0.05). In the invasion test, the number of cells that passed through the chambers in the RRM2-siRNA group was 81 ± 3, which was lower than that in the negative control (289 ± 7) and blank control groups (301 ± 7.2). These differences were statistically significant (P < 0.01). Our data suggest that RRM2 overexpression may be associated with CRC progression. RRM2 silencing by siRNA may inhibit the hyperplasia and invasiveness of CRC cells, suggesting that RRM2 may play an important role in the infiltration and metastasis of CRC, which is a potential therapeutic strategy in CRC. In addition, RRM2 depletion increased UV sensitivity.
CONCLUSION: These findings suggest that RRM2 may be a facilitating factor in colorectal tumorigenesis and UV-induced DNA damage repair.

Entities:  

Keywords:  Cancinogenesis; Colorectal cancers; Metabolic genes; Ribonucleotide reductase M2; Tissue microarray; Ultraviolet irradiation

Mesh:

Substances:

Year:  2012        PMID: 23002339      PMCID: PMC3442208          DOI: 10.3748/wjg.v18.i34.4704

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  34 in total

Review 1.  Prolapsing congenital polyp of posterior urethra and urethral duplication associated with imperforate anus.

Authors:  R M Chiaramonte; M A Rich; W A Brock
Journal:  Urology       Date:  1992-12       Impact factor: 2.649

2.  S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs.

Authors:  S Björklund; S Skog; B Tribukait; L Thelander
Journal:  Biochemistry       Date:  1990-06-12       Impact factor: 3.162

Review 3.  Ribonucleotide reductases.

Authors:  Pär Nordlund; Peter Reichard
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

4.  Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase.

Authors:  L Thelander; P Berg
Journal:  Mol Cell Biol       Date:  1986-10       Impact factor: 4.272

5.  The gene for ornithine decarboxylase is co-amplified in hydroxyurea-resistant hamster cells.

Authors:  P R Srinivasan; P N Tonin; E J Wensing; W H Lewis
Journal:  J Biol Chem       Date:  1987-09-15       Impact factor: 5.157

6.  Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential.

Authors:  H Fan; C Villegas; J A Wright
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

7.  Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential.

Authors:  B S Zhou; P Tsai; R Ker; J Tsai; R Ho; J Yu; J Shih; Y Yen
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 4.510

Review 8.  Ribonucleotide reductases.

Authors:  A Jordan; P Reichard
Journal:  Annu Rev Biochem       Date:  1998       Impact factor: 23.643

9.  Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells.

Authors:  B S Zhou; N Y Hsu; B C Pan; J H Doroshow; Y Yen
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

10.  Early induction of ribonucleotide reductase gene expression by transforming growth factor beta 1 in malignant H-ras transformed cell lines.

Authors:  R A Hurta; S K Samuel; A H Greenberg; J A Wright
Journal:  J Biol Chem       Date:  1991-12-15       Impact factor: 5.157

View more
  18 in total

Review 1.  Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.

Authors:  Sarah E Huff; Jordan M Winter; Chris G Dealwis
Journal:  Biomolecules       Date:  2022-06-10

2.  Identification of Key Components in Colon Adenocarcinoma Using Transcriptome to Interactome Multilayer Framework.

Authors:  Ehsan Pournoor; Zaynab Mousavian; Abbas Nowzari Dalini; Ali Masoudi-Nejad
Journal:  Sci Rep       Date:  2020-03-19       Impact factor: 4.379

3.  High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma.

Authors:  Cheng-Yu Jin; Liang Du; A-Han Nuerlan; Xiao-Lei Wang; Yong-Wei Yang; Rui Guo
Journal:  Aging (Albany NY)       Date:  2020-12-19       Impact factor: 5.682

4.  Genome Wide Expression Profiling of Cancer Cell Lines Cultured in Microgravity Reveals Significant Dysregulation of Cell Cycle and MicroRNA Gene Networks.

Authors:  Prasanna Vidyasekar; Pavithra Shyamsunder; Rajpranap Arun; Rajalakshmi Santhakumar; Nand Kishore Kapadia; Ravi Kumar; Rama Shanker Verma
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

5.  Ribonucleotide reductase subunit M2 predicts survival in subgroups of patients with non-small cell lung carcinoma: effects of gender and smoking status.

Authors:  Vei Mah; Mohammad Alavi; Diana C Márquez-Garbán; Erin L Maresh; Sara R Kim; Steve Horvath; Lora Bagryanova; Sara Huerta-Yepez; David Chia; Richard Pietras; Lee Goodglick
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

6.  LncSubpathway: a novel approach for identifying dysfunctional subpathways associated with risk lncRNAs by integrating lncRNA and mRNA expression profiles and pathway topologies.

Authors:  Yanjun Xu; Feng Li; Tan Wu; Yingqi Xu; Haixiu Yang; Qun Dong; Meiyu Zheng; Desi Shang; Chunlong Zhang; Yunpeng Zhang; Xia Li
Journal:  Oncotarget       Date:  2017-02-28

7.  Identification of Common Genes Refers to Colorectal Carcinogenesis with Paired Cancer and Noncancer Samples.

Authors:  Lihua Zhang; Yonglong Yang; Lin Cheng; Yu Cheng; Hong-Hao Zhou; Zhi-Rong Tan
Journal:  Dis Markers       Date:  2018-01-30       Impact factor: 3.434

8.  Bone marrow-derived mesenchymal stromal cells promote colorectal cancer cell death under low-dose irradiation.

Authors:  Hao Feng; Jing-Kun Zhao; Tobias S Schiergens; Pu-Xiongzhi Wang; Bao-Chi Ou; Rami Al-Sayegh; Ming-Lun Li; Ai-Guo Lu; Shuai Yin; Wolfgang E Thasler
Journal:  Br J Cancer       Date:  2018-01-02       Impact factor: 7.640

9.  Identification of Core Gene Expression Signature and Key Pathways in Colorectal Cancer.

Authors:  Xiang Ding; Houyu Duan; Hesheng Luo
Journal:  Front Genet       Date:  2020-02-21       Impact factor: 4.599

10.  Comprehensive analysis reveals a metabolic ten-gene signature in hepatocellular carcinoma.

Authors:  Zhipeng Zhu; Lulu Li; Jiuhua Xu; Weipeng Ye; Borong Chen; Junjie Zeng; Zhengjie Huang
Journal:  PeerJ       Date:  2020-05-26       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.